Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Aptevo Therapeutics’ dense biotech disclosures can feel like reading a second language. Clinical-stage companies such as Aptevo juggle milestone payments, patent filings, and trial data across dozens of forms, so spotting cash-runway updates or understanding toxicology results is challenging. Stock Titan translates every Aptevo Therapeutics SEC filing into plain English, turning 300-page documents into concise briefs backed by AI-powered summaries and real-time alerts.
Whether you need the Aptevo Therapeutics quarterly earnings report 10-Q filing or want Aptevo Therapeutics insider trading Form 4 transactions, our platform surfaces what matters: burn rate trends, dilution risk, and executive stock incentives. Proprietary algorithms flag each Aptevo Therapeutics 8-K material events explained in minutes, while interactive tables track Aptevo Therapeutics executive stock transactions Form 4 as they appear on EDGAR. If you are comparing trial milestones, the Aptevo Therapeutics annual report 10-K simplified section highlights pipeline progress, key risk factors, and intellectual-property status.
Investors typically ask how to read Aptevo Therapeutics’ proxy statement executive compensation or where to find Aptevo Therapeutics earnings report filing analysis. Here’s the streamlined path:
- Instant notice of Aptevo Therapeutics Form 4 insider transactions real-time
- Side-by-side redline of sequential 10-Q footnotes for faster trend analysis
- Natural-language answers for understanding Aptevo Therapeutics SEC documents with AI
Stop skimming PDFs. Our AI technology extracts segment data, clinical updates, and forward-looking statements so you can focus on decisions, not document searches. Aptevo Therapeutics SEC filings explained simply—always current, always in context.
Abdun-Nabi Daniel, identified as a director of Aptevo Therapeutics, reported the grant of 7,200 Restricted Stock Units (RSUs) with a transaction date of 08/06/2025. The filing states the RSUs convert one-for-one into common stock of the issuer.
The RSUs are reported as directly owned following the grant and are set to vest in full on the first anniversary of the grant date. The Form 4 shows no sale or disposition associated with this reported transaction and lists beneficial ownership after the transaction as 7,200 shares (upon conversion).
Aptevo Therapeutics Inc. (APVO) reports that Daphne Taylor, the company's SVP and Chief Financial Officer, acquired 11,500 Restricted Stock Units (RSUs) on 08/06/2025. The filing shows these RSUs convert one-for-one into common stock and are recorded as a direct holding following the reported transaction.
The RSUs carry a $0 price in the filing and vest in full on the first anniversary of the grant, meaning they will convert into 11,500 common shares when vested. The form reflects an insider equity grant reported under Form 4 and does not disclose the company’s total outstanding shares, so the percentage dilution from this grant cannot be determined from this filing alone.
Aptevo Therapeutics director Grant Grady III reported a grant of 7,200 Restricted Stock Units (RSUs) in a Form 4 covering a transaction dated 08/06/2025. The RSUs convert one-for-one into common stock and are reported as direct holdings of 7,200 shares following the grant. The RSUs vest in full on the first anniversary of the grant.
The form is signed by attorney-in-fact SoYoung Kwon on 08/08/2025, and the filing shows a $0 price for the RSUs.
Aptevo Therapeutics reported a compensation-related equity award to Dirk Huebner, the companys SVP and Chief Medical Officer. On 08/06/2025 Mr. Huebner was granted 11,500 Restricted Stock Units (RSUs) that convert on a one-for-one basis into common stock, reflecting a potential issuance of 11,500 shares upon settlement.
The RSUs vest in full on the first anniversary of the grant, so the shares become deliverable only after that one-year vesting period. The filing shows the ownership form as direct and the RSUs carry a $0.00 exercise/conversion price, indicating a straight equity award rather than a purchase-based option.
Aptevo Therapeutics director John Niederhuber was reported to have acquired 7,200 restricted stock units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock, and the transaction is recorded as an acquisition at a $0 price, indicating no cash was paid for the award. The filing shows the resulting beneficial interest as 7,200 RSUs held in a direct ownership form.
The RSUs are described to vest in full on the first anniversary of the grant, at which point they will convert into 7,200 common shares if the vesting conditions are satisfied. The Form 4 is filed by a single reporting person and contains only this equity award; it does not provide information on total outstanding shares or percentage ownership, so the document alone does not quantify dilution or ownership percentage.
Jeffrey G. Lamothe, identified as EVP and COO of Aptevo Therapeutics (APVO), was granted 17,300 restricted stock units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock, the grant is recorded as an acquisition of derivative securities at a reported price of $0.00, and the filing shows 17,300 shares of direct beneficial ownership following the transaction.
The RSUs vest in full on the first anniversary of the grant date, so conversion into common shares is contingent on that vesting event. The Form 4 discloses this equity award and the resulting change in the reporting person's beneficial ownership for SEC transparency.
Aptevo Therapeutics' President and CEO, Marvin L. White, was granted 30,000 Restricted Stock Units (RSUs) with a transaction date of 08/06/2025. The RSUs convert one-for-one into common stock and are reported as direct beneficial ownership. The awards vest in full on the first anniversary of the grant, at which time 30,000 common shares become issuable.
Aptevo Therapeutics director Barbara Lopez Kunz was granted 7,200 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock and the award vests in full on the first anniversary of the grant date. The reported position is held directly and the RSUs are recorded with a $0 per-share conversion price as described in the filing.
Aptevo Therapeutics officer SoYoung Kwon received a grant of 11,500 restricted stock units (RSUs) reported with a transaction date of 08/06/2025. Each RSU converts one-for-one into common stock and the RSUs vest in full on the first anniversary of the grant, creating the potential issuance of 11,500 common shares at no cash price. The reported ownership following the transaction is direct. This disclosure reflects a routine equity-based compensation award to an officer rather than a cash transaction.
Aptevo Therapeutics director Harsanyi Zsolt was granted 7,200 restricted stock units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock and is reported as a direct beneficial interest. The award carries a $0 price and vests in full on the first anniversary of the grant, meaning the holder would receive 7,200 common shares if vesting conditions are met. The reporting form lists a single reporting person and the grant was executed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Aptevo Therapeutics (APVO)?
What is the market cap of Aptevo Therapeutics (APVO)?
